SS47 (TFA)

CAT: 0804-HY-146231A-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-146231A-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies[1]. SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
UNSPSC
12352005
Target
MAP4K; PROTACs
Type
Reference compound
Related Pathways
MAPK/ERK Pathway; PROTAC
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ss47-tfa.html
Purity
99.88
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC=C3OCCOCCOCCOCCOCCC(N4CCC(C5=NC=C(C6=CC(OCC7=CC=CC(C#CC(C)(O)C)=C7)=C(N)N=C6)S5)CC4)=O)=O.OC(C(F)(F)F)=O
Molecular Formula
C51H57F3N6O14S
Molecular Weight
1067.09
References & Citations
[1]Jingwen Si, et al. Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies. Cancer Cell. 2020 Oct 12;38 (4) :551-566.e11.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products